Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 14-17 April 2020

PRAC concludes Picato’s risks are greater than its benefits.

Philippe Calandra 20 April 2020 All news
  • ← MHRA regulatory flexibilities resulting from coronavirus (COVID-19)
  • Clinical trials managing patients with COVID-19: progress report on projects authorized by the ANSM – Information point →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Happy Holidays from the Pharmya team!
  • A common EU approach to data transparency in medicine regulation
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024
Copyright © 2018 - Pharmya - Legal terms - Quality Policy